Treatment of depressive and anxiety disorders during pregnancy and lactation: A case study DOI Creative Commons

Teodora Inić,

Mina Cvjetković-Bošnjak, Dušan Kuljančić

et al.

SANAMED, Journal Year: 2024, Volume and Issue: 19(3), P. 319 - 324

Published: Jan. 1, 2024

Introduction: Depressive and anxiety disorders are among the most common psychiatric conditions, as stated by WHO in 2015. These often manifest during adolescence or young adulthood, making it unsurprising for women pregnancy lactation periods to experience either a first manifestation recurrence of symptoms. When these occur lactation, antidepressant treatment may be required per established protocols. However, concerns arise patients, such as: "Is this medication safe me my baby? Could negatively affect baby's development?" hesitations can sometimes extend healthcare providers if they lack adequate education on topic. Therapeutic guidelines worldwide recommend psychotherapy mild symptoms, whereas pharmacotherapy, combined with , is carefully considered moderate Case Report: This paper presents three case studies pregnant depressive disorders. The involves patient prenatal depression who achieved complete remission after starting therapy. second highlights symptoms following dis-continuation psychopharmaceuticals. third emphasizes importance individualized plans illustrates previously remission. Conclusion: Pregnant mental health challenges have significant about using psychopharmaceuticals pregnancy. aims underscore that appropriate selection dosage medications lead without adverse effects mother child.

Language: Английский

Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy DOI
Maike Scherf‐Clavel, Anna Linda Leutritz,

Andrea Gehrmann

et al.

British Journal of Clinical Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Pharmacotherapy of maternal peripartum depression is an increasing challenge. Amitriptyline (AMI) the most often used tricyclic antidepressant during pregnancy, but knowledge on pharmacokinetics in this special phase lacking. Physiologically based pharmacokinetic (PBPK) modelling a powerful tool to better understand pregnancy-induced changes medication. We aimed improve about AMI pregnancy using PBPK modelling. Consequently, we add new information for effective and safe pharmacotherapy pregnant women. A model, including AMI, also its active metabolite nortriptyline (NOR), was developed investigate after administration. The predicted drug exposure compared observed concentrations patients clinical routine. model set up PK-Sim Version 11. Serum concentration profiles were described successfully. During moiety serum (AMI + NOR) did not change; however, increased, whereas NOR decreased. With added valuable (increased concentration, decreased concentration). For practice treating physician should be aware that despite comparable before tolerability may affected due increased as consequence anticholinergic effects. To keep risk therapy discontinuation low, suggest performing therapeutic monitoring, especially check concentration.

Language: Английский

Citations

0
Addressing the Use of Antidepressants in the Preconception Period DOI

Evelyn Addo-Wallace,

Melicia Escobar

Journal of Psychosocial Nursing and Mental Health Services, Journal Year: 2025, Volume and Issue: 63(5), P. 9 - 12

Published: May 1, 2025

Depression affects many individuals who desire pregnancy, peaking during the reproductive years. Black, Latine, Indigenous, and Asian American are at increased risk for depression due to inequitable distribution of structural social determinants health, resulting in poorer perinatal neonatal health outcomes. The preconception visit is ideal comprehensive mental screening alongside referrals supportive care measures. Advanced practice nurses (APNs) should conduct a thorough medication reconciliation assess risks period, related newborn feeding. When weighed against untreated or undertreated depression, minimal associated with antidepressants may be well worth it. As part collaborative, multispecialty team, APNs can help patients determine plan that works them, informed by best practice, optimize patients' wellness through preconception, postpartum periods. [ Journal Psychosocial Nursing Mental Health Services, 63 (5), 9–12.]

Language: Английский

Citations

0
Treatment of depressive and anxiety disorders during pregnancy and lactation: A case study DOI Creative Commons

Teodora Inić,

Mina Cvjetković-Bošnjak, Dušan Kuljančić

et al.

SANAMED, Journal Year: 2024, Volume and Issue: 19(3), P. 319 - 324

Published: Jan. 1, 2024

Introduction: Depressive and anxiety disorders are among the most common psychiatric conditions, as stated by WHO in 2015. These often manifest during adolescence or young adulthood, making it unsurprising for women pregnancy lactation periods to experience either a first manifestation recurrence of symptoms. When these occur lactation, antidepressant treatment may be required per established protocols. However, concerns arise patients, such as: "Is this medication safe me my baby? Could negatively affect baby's development?" hesitations can sometimes extend healthcare providers if they lack adequate education on topic. Therapeutic guidelines worldwide recommend psychotherapy mild symptoms, whereas pharmacotherapy, combined with , is carefully considered moderate Case Report: This paper presents three case studies pregnant depressive disorders. The involves patient prenatal depression who achieved complete remission after starting therapy. second highlights symptoms following dis-continuation psychopharmaceuticals. third emphasizes importance individualized plans illustrates previously remission. Conclusion: Pregnant mental health challenges have significant about using psychopharmaceuticals pregnancy. aims underscore that appropriate selection dosage medications lead without adverse effects mother child.

Language: Английский

Citations

0